Published in Br J Clin Pharmacol on July 03, 2006
Feeding and Bleeding: The Institutional Banalization of Risk to Healthy Volunteers in Phase I Pharmaceutical Clinical Trials. Sci Technol Human Values (2015) 1.07
Stopped hearts, amputated toes and NASA: contemporary legends among healthy volunteers in US phase I clinical trials. Sociol Health Illn (2015) 1.00
Inadequate dissemination of phase I trials: a retrospective cohort study. PLoS Med (2009) 0.96
A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group. Br J Clin Pharmacol (2010) 0.93
The bridging function of clinical pharmacology. Eur J Clin Pharmacol (2007) 0.88
From pharmacology to immunopharmacology. Br J Clin Pharmacol (2006) 0.87
Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe? Br J Clin Pharmacol (2013) 0.84
Using "clinical trial diaries" to track patterns of participation for serial healthy volunteers in U.S. phase I studies. J Empir Res Hum Res Ethics (2015) 0.82
Risks of phase I research with healthy participants: A systematic review. Clin Trials (2015) 0.81
Clinical pharmacology in everyday clinical care. Eur J Clin Pharmacol (2013) 0.75
Adverse events in phase-I studies: a report in 1015 healthy volunteers. Eur J Clin Pharmacol (1998) 1.73
Inquiry into adverse events in trial blames drug, not study design. BMJ (2006) 1.64
Adverse event associated with methionine loading test: a case report. Arterioscler Thromb Vasc Biol (2002) 1.01
Healthy volunteer dies in US physiology study. Lancet (2001) 0.98
Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol (2009) 1.24
Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers. Patient Prefer Adherence (2010) 1.17
Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine (2013) 1.11
Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine. Hum Vaccin (2010) 1.05
A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group. Br J Clin Pharmacol (2010) 0.93
Effect of low-fat, fermented milk enriched with plant sterols on serum lipid profile and oxidative stress in moderate hypercholesterolemia. Am J Clin Nutr (2007) 0.92
Supplementation of the diet with the functional fiber PolyGlycoplex is well tolerated by healthy subjects in a clinical trial. Nutr J (2009) 0.88
Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trial. J Transl Med (2014) 0.81
Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation. Int J Clin Pharmacol Ther (2013) 0.78
Digestive Symptoms in Healthy People and Subjects With Irritable Bowel Syndrome: Validation of Symptom Frequency Questionnaire. J Clin Gastroenterol (2015) 0.77
A bioavailability study comparing two oral formulations containing zinc (Zn bis-glycinate vs. Zn gluconate) after a single administration to twelve healthy female volunteers. Int J Vitam Nutr Res (2007) 0.77
Effect on blood lipids of two daily servings of Camembert cheese. An intervention trial in mildly hypercholesterolemic subjects. Int J Food Sci Nutr (2014) 0.76
Absence of psychostimulant effects of a supratherapeutic dose of tianeptine: a placebo-controlled study versus methylphenidate in young healthy volunteers. J Clin Psychopharmacol (2011) 0.76
Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor. Thromb Haemost (2005) 0.75
Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome. Cerebrovasc Dis (2016) 0.75